Literature DB >> 10511310

Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts.

A Kilbey1, V Stephens, C Bartholomew.   

Abstract

The Evi-1 transcriptional repressor protein has two distinct zinc finger DNA binding domains designated ZF1 and ZF2 and is implicated in the progression of human and murine leukemias, in which it is abnormally expressed. In this report, we show that Evi-1-expressing Rat1 fibroblasts are anchorage independent, have an abbreviated G1 phase of the cell cycle, and have a reduced requirement for serum mitogens for S-phase entry. These biological changes are accompanied by a moderately increased production of cell cycle-regulatory proteins cyclin A and cyclin-dependent kinase (Cdk) 2, a dramatic deregulation of Cdk2 kinase activity, and a corresponding increase in the levels of hyperphosphorylated retinoblastoma protein (pRb). We show that the elevated cyclin A-Cdk2 activity is due to the combination of increased accumulation and stabilization of cyclin A bound to a faster-migrating species of Cdk2 believed to be the active threonine 160 phosphorylated form and a substantial reduction in complexed p27. Cyclin E kinase activity is also elevated due to a reduction in p27. A significant reduction in total cellular p27 protein levels and a moderate reduction in p27 mRNA are observed, but no changes in Cdk regulatory kinases and phosphatases occur. The Evi-1 transcriptional repressor domain and the ZF1 DNA binding domain are required for both cell transformation and induction of Cdk2 catalytic activity. We propose that one consequence of Evi-1 expression is to repress the transcription of target genes, which may include p27, that deregulate the normal control of the G1 phase of the cell cycle, providing a cellular proliferative advantage that contributes to transformation in vitro and leukemogenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511310

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  10 in total

1.  Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome.

Authors:  Jerome Dickstein; Vitalyi Senyuk; Kavitha Premanand; Leopoldo Laricchia-Robbio; Peng Xu; Francesca Cattaneo; Raffaella Fazzina; Giuseppina Nucifora
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-06       Impact factor: 11.205

2.  EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements.

Authors:  Michael Wilson; Vasiliki Tsakraklides; Minh Tran; Ying-Yi Xiao; Yi Zhang; Archibald S Perkins
Journal:  J Biol Chem       Date:  2016-04-21       Impact factor: 5.157

3.  Ex vivo expansion of retrovirally transduced primate CD34+ cells results in overrepresentation of clones with MDS1/EVI1 insertion sites in the myeloid lineage after transplantation.

Authors:  Stephanie Sellers; Theotonius J Gomes; Andre Larochelle; Rebecca Lopez; Rima Adler; Allen Krouse; Robert E Donahue; Richard W Childs; Cynthia E Dunbar
Journal:  Mol Ther       Date:  2010-06-22       Impact factor: 11.454

4.  Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase.

Authors:  Kadin Karakaya; Friederike Herbst; Claudia Ball; Hanno Glimm; Alwin Krämer; Harald Löffler
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

5.  Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability.

Authors:  Eun Ji Choi; Min Sung Kim; Sang Yong Song; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2016-09-13       Impact factor: 3.201

6.  Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.

Authors:  Carolyn Glass; Charles Wuertzer; Xiaohui Cui; Yingtao Bi; Ramana Davuluri; Ying-Yi Xiao; Michael Wilson; Kristina Owens; Yi Zhang; Archibald Perkins
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

Review 7.  Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.

Authors:  M Kretzschmar
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

8.  RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks.

Authors:  Sophie G Kellaway; Peter Keane; Ella Kennett; Constanze Bonifer
Journal:  Haematologica       Date:  2021-06-01       Impact factor: 9.941

9.  Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability.

Authors:  Daniel J White; Richard D Unwin; Eric Bindels; Andrew Pierce; Hsiang-Ying Teng; Joanne Muter; Brigit Greystoke; Tim D Somerville; John Griffiths; Simon Lovell; Tim C P Somervaille; Ruud Delwel; Anthony D Whetton; Stefan Meyer
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

Review 10.  Zinc, infections and immunosenescence.

Authors:  E Mocchegiani; R Giacconi; M Muzzioli; C Cipriano
Journal:  Mech Ageing Dev       Date:  2000-12-20       Impact factor: 5.432

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.